

REMARKS/ARGUMENTS

Status of the Claims

Upon entry of the present amendment, claims 4-8 and 15-23 are pending. Claims 4-6 are amended. New claims 15-23 are added.

Claims 4-6 are amended to set forth specific concentrations of HGF and FGF-2. Support is found, for example, on page 16, line 24 through page 17, line 1.

New claims 15 and 16 find support, for example, on page 16, line 24 through page 17, line 1.

New claim 17 finds support, for example, on page 29, lines 15-16.

New claim 18 finds support, for example, on page 37, line 16 through page 38, line 6.

New claims 19-21 find support, for example, on page 29, lines 3-22 and throughout the specification. It is clear that the culturing conditions of the present invention were carried out under atmospheric oxygen levels.

New claim 22, finds support, for example, on page 8, lines 17-20.

New claim 23 finds support, for example, on page 8, lines 21-22.

The present amendments are necessary to place the claims in form for allowance or to reduce issues for appeal. No new matter is added by the present amendments, and the Examiner is respectfully requested to enter them.

Claim Objections

The Examiner objected to claims 4-6 for reciting non-elected subject matter. This objection is obviated by amendment of claims 4-6 to cancel recitation of non-elected subject matter.

Rejections under 35 U.S.C. § 112, second paragraph

The Examiner has rejected claims 6-8 under 35 U.S.C. § 112, second paragraph, as allegedly unclear. Applicants do not agree with the Examiner. However, in the interest of

furthering prosecution, Applicants have amended claim 6 to set forth the step of culturing cells under conditions that allow their differentiation into a population of cells containing neurons and glia.

Rejection under 35 U.S.C. § 102(e)

The Examiner has maintained the rejection of claims 4-6 and 8 under 35 U.S.C. § 102(e) as allegedly anticipated by U.S. Patent No. 6,589,728 (“Csete”). Applicants do not agree with the Examiner. However, in the interest of furthering prosecution, Applicants have amended claims 4-6 to set forth particular concentrations of HGF and FGF-2. Csete does not teach or suggest particularly using HGF and FGF-2 to culture, proliferate or differentiate neural stem cells, much less teach or suggest a particular concentration range for either growth factor. Furthermore, the invention in Csete relies on subatmospheric oxygen levels in culture (*i.e.*, less than 12% in the claims). This is reflected in the abstract and claims of Csete.

The Examiner is respectfully reminded that the present invention is a selection invention particularly directed to the culture, proliferation and differentiation of neural stem cells. The passages in columns 7 and 15 of Csete identified by the Examiner are not entirely consistent with each other. The passage at column 7, lines 42-62 is concerned with stem cells generally and not neural stem cells in particular. The passage at column 7 does not teach or suggest particularly combining HGF with FGF-2 (*a.k.a.*, bFGF) to culture, proliferate or differentiate any kind of stem cell, much less particularly neural stem cells.

The passage at column 15, lines 51-65 of Csete is expressly directed to isolating and culturing neural stem cells. Csete discloses that neuroepithelial stem cells can be cultured and proliferated in FGF-2 (bFGF), but does not disclose or suggest combining FGF-2 with HGF. With respect to differentiation of neural stem cells into neurons and glia, Csete affirmatively states that the FGF-2 (bFGF) is removed and replaced with media lacking FGF-2. Therefore, in the passage at column 15, lines 63-65, Csete expressly teaches that differentiation of neural stem cells is performed in the absence of FGF-2 and does not teach or suggest adding HGF for the purpose of culturing, proliferating or differentiating neural stem cells. The Examiner can not

give greater weight to the general disclosure of Csete in column 7 while ignoring the disclosure particular to neural stem cells at column 15.

Because Csete does not teach or suggest each and every element of the claimed methods, Csete does not anticipate the present invention. Accordingly, the Examiner is respectfully requested to withdraw this rejection.

Rejection under 35 U.S.C. § 103(a)

The Examiner has rejected claim 7 under 35 U.S.C. § 103(a) as allegedly obvious over Csete in view of U.S. Patent No. 5,753,505 ("Luskin"). To the extent that the present rejection applies to the present claims, Applicants respectfully traverse.

Applicants maintain the position that the combined disclosures of Csete and Luskin do not teach or suggest all of the steps and elements of the claimed methods. The Examiner is respectfully reminded that the present methods are a selection invention particularly directed to the culture, proliferation and differentiation of neural stem cells by culturing them in a growth medium comprising the particularly selected combination of HGF and FGF-2. As discussed previously, in the passage in column 7 of Csete, no particular combination of growth factors is called out and no particular stem cell type is called out. As a matter of enablement of Csete as a reference, the skilled person is still left to determine which out of the myriad of permutations of growth factors and stem cell types to match up for the culture, proliferation and/or differentiation conditions particular to neural stem cells. Where Csete does expressly discuss neural stem cells in the passage in column 15, Csete teaches away from the present methods by teaching that FGF-2 is removed prior to differentiation neural stem cells. Csete makes absolutely *no mention of HGF in the growth medium of neural stem cells*.

With respect to the amended claims, Csete does not teach or suggest the particular concentrations of growth factors. Csete certainly teaches against the use of atmospheric concentrations of oxygen in culturing, proliferating, or differentiating any kind of stem cell, including neural stem cells. *See, e.g.*, abstract, summary and claims of Csete. As stated previously, Luskin does not cure the deficiencies of Csete. Luskin discloses adding nerve

growth factor (NGF) or brain-derived neurotrophic factor (BDNF) to the growth medium of neural stem cells, but does not teach or suggest in any way that hepatocyte growth factor would find use in culturing, proliferating or differentiation neural stem cells. Based on the disclosures of Csete and Luskin, the skilled person would have no reason to expect that a liver cell growth factor should promote differentiation of nerve stem cells, for example, into neurons.

In any case, Applicants have rebutted any alleged *prima facie* case of obviousness by demonstrating an unexpected synergistic effect of HGF and FGF-2 in promoting the growth and differentiation of neural stem cells. This is shown in columns 1-3 of Table 1 on page 35 of the present application. The Examiner alleges that the synergistic effects of HGF and FGF2 are not unexpected because HGF and FGF-2 are structurally and functionally distinct growth factors. *See*, pages 4-5 of the present Office Action. However, FGF-2 and EGF also are structurally and functionally distinct growth factors,¹ and their combined effects were less than additive. *See*, columns 2 (FGF-2 only), 4 (EGF only) and 6 (FGF-2 and EGF) of Table 1. There is no *a priori* reason for the skilled person to expect that the combination of HGF and FGF-2 should be synergistic and the combination of FGF-2 and EGF be less than additive in promoting the proliferation of neural stem cells.

Also, the differentiated neural cell populations are different in the presence or absence of HGF. In the presence of HGF, a majority of the differentiated cells are neurons. In the presence of EGF and FGF-2, but in the absence of HGF, only about 30% of the differentiated cells are neurons. *See, e.g.*, page 37, lines 16-24 of the present application.

In view of the foregoing, the combined disclosures of Csete and Luskin do not render the present methods obvious. Accordingly, the Examiner is respectfully requested to withdraw the present rejection.

¹ Amino acid sequences and BLAST alignments of human HGF, FGF-2 and EGF are attached as Exhibit A.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance and an action to that end is respectfully requested.




If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Jennifer L. Wahlsten
Reg. No. 46,226

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
Attachments
JLW:jlw
61201308 v1

[PubMed](#)
[Nucleotide](#)
[Protein](#)
[Genome](#)
[Structure](#)
[PMC](#)
[Taxonomy](#)
[OMIM](#)
[Books](#)

[Search](#)
[Protein](#)
[for](#)
[Limits](#)
[Preview/Index](#)
[History](#)
[Clipboard](#)
[Details](#)

[Display](#)
[GenPept](#)
[Show](#)

[Send to](#)

Range: from to
 Features:
 ☐ SNP
 ☒ CDD
 ☒ HPRD

[Refresh](#)

My N
[\[Sign In\]](#)
[\[Regis\]](#)

☐ 1: NP_001954. Reports epidermal growth ...[gi:4503491]

BLink, Conserved
 Domains, Links

[Comment](#) [Features](#) [Sequence](#)

LOCUS NP_001954 1207 aa linear PRI 22-OCT-2007
 DEFINITION epidermal growth factor (beta-urogastrone) [Homo sapiens].
 ACCESSION NP_001954
 VERSION NP_001954.1 GI:4503491
 DBSOURCE REFSEQ: accession [NM_001963.2](#)
 KEYWORDS .
 SOURCE Homo sapiens (human)
 ORGANISM [Homo sapiens](#)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
 Catarrhini; Hominidae; Homo.
 REFERENCE 1 (residues 1 to 1207)
 AUTHORS Toyoda,T., Nakamura,K., Yamada,K., Thanseem,I., Anitha,A., Suda,S.,
 Tsujii,M., Iwayama,Y., Hattori,E., Toyota,T., Miyachi,T., Iwata,Y.,
 Suzuki,K., Matsuzaki,H., Kawai,M., Sekine,Y., Tsuchiya,K.,
 Sugihara,G., Ouchi,Y., Sugiyama,T., Takei,N., Yoshikawa,T. and
 Mori,N.
 TITLE SNP analyses of growth factor genes EGF, TGFbeta-1, and HGF reveal
 haplotypic association of EGF with autism
 JOURNAL Biochem. Biophys. Res. Commun. 360 (4), 715-720 (2007)
 PUBMED [17626784](#)
 REMARK GeneRIF: suggest a possible role of EGF in the pathogenesis of
 autism
 REFERENCE 2 (residues 1 to 1207)
 AUTHORS Diehl,K.M., Grewal,N., Ethier,S.P. and Woods-Ignatoski,K.M.
 TITLE p38MAPK-activated AKT in HER-2 overexpressing human breast cancer
 cells acts as an EGF-independent survival signal
 JOURNAL J. Surg. Res. 142 (1), 162-169 (2007)
 PUBMED [17612563](#)
 REMARK GeneRIF: In the absence of EGF, p38MAPK-activated AKT is necessary
 for HER-2 overexpressing human breast cancer cells to survive and
 to form colonies in soft agar.
 REFERENCE 3 (residues 1 to 1207)
 AUTHORS Meisdalen,K., Dajani,O.F., Christoffersen,T. and Sandnes,D.
 TITLE Prostaglandins enhance epidermal growth factor-induced DNA
 synthesis in hepatocytes by stimulation of E prostanoid 3 and F
 prostanoid receptors
 JOURNAL J. Pharmacol. Exp. Ther. 322 (3), 1044-1050 (2007)
 PUBMED [17567965](#)
 REMARK GeneRIF: role of E prostanoid receptors EP1, EP2, & EP3 and F
 prostanoid receptors in enhancing the growth-stimulatory effect of
 epidermal growth factor in cultured hepatocytes

Exhibit A

- REFERENCE 4 (residues 1 to 1207)
 AUTHORS Su,X., Kong,C. and Stahl,P.D.
 TITLE GAPex-5 mediates ubiquitination, trafficking, and degradation of epidermal growth factor receptor
 JOURNAL J. Biol. Chem. 282 (29), 21278-21284 (2007)
 PUBMED [17545148](#)
 REMARK GeneRIF: EGF-stimulated receptor ubiquitination and trafficking are mediated via GAPex-5: GAPex-5-mediated EGFR ubiquitination is independent of Rab5 activation
- REFERENCE 5 (residues 1 to 1207)
 AUTHORS Durer,U., Hartig,R., Bang,S., Thim,L. and Hoffmann,W.
 TITLE TFF3 and EGF induce different migration patterns of intestinal epithelial cells in vitro and trigger increased internalization of E-cadherin
 JOURNAL Cell. Physiol. Biochem. 20 (5), 329-346 (2007)
 PUBMED [17762162](#)
 REMARK GeneRIF: trefoil factor 3, in contrast to EGF, enhanced a collective cell migration ensuring a precise coverage of the re-populated area avoiding gaps
- REFERENCE 6 (sites)
 AUTHORS Skidgel,R.A., McGwire,G.B. and Li,X.Y.
 TITLE Membrane anchoring and release of carboxypeptidase M: implications for extracellular hydrolysis of peptide hormones
 JOURNAL Immunopharmacology 32 (1-3), 48-52 (1996)
 PUBMED [8796265](#)
- REFERENCE 7 (sites)
 AUTHORS McGwire,G.B. and Skidgel,R.A.
 TITLE Extracellular conversion of epidermal growth factor (EGF) to des-Arg53-EGF by carboxypeptidase M
 JOURNAL J. Biol. Chem. 270 (29), 17154-17158 (1995)
 PUBMED [7615511](#)
- REFERENCE 8 (residues 1 to 1207)
 AUTHORS Ishibashi,T., Bottaro,D.P., Chan,A., Miki,T. and Aaronson,S.A.
 TITLE Expression cloning of a human dual-specificity phosphatase
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 89 (24), 12170-12174 (1992)
 PUBMED [1281549](#)
- REFERENCE 9 (residues 1 to 1207)
 AUTHORS Gout,I., Dhand,R., Panayotou,G., Fry,M.J., Hiles,I., Otsu,M. and Waterfield,M.D.
 TITLE Expression and characterization of the p85 subunit of the phosphatidylinositol 3-kinase complex and a related p85 beta protein by using the baculovirus expression system
 JOURNAL Biochem. J. 288 (PT 2), 395-405 (1992)
 PUBMED [1334406](#)
- REFERENCE 10 (residues 1 to 1207)
 AUTHORS Hommel,U., Harvey,T.S., Driscoll,P.C. and Campbell,I.D.
 TITLE Human epidermal growth factor. High resolution solution structure and comparison with human transforming growth factor alpha
 JOURNAL J. Mol. Biol. 227 (1), 271-282 (1992)
 PUBMED [1522591](#)
- REFERENCE 11 (residues 1 to 1207)
 AUTHORS Lei,Z.M. and Rao,C.V.
 TITLE Expression of epidermal growth factor (EGF) receptor and its ligands, EGF and transforming growth factor-alpha, in human fallopian tubes
 JOURNAL Endocrinology 131 (2), 947-957 (1992)
 PUBMED [1639032](#)
- REFERENCE 12 (residues 1 to 1207)
 AUTHORS Gregory,H. and Preston,B.M.
 TITLE The primary structure of human urogastrone

JOURNAL Int. J. Pept. Protein Res. 9 (2), 107-118 (1977)
 PUBMED 300079
 COMMENT REVIEWED [REFSEQ](#): This record has been curated by NCBI staff. The reference sequence was derived from [X04571.1](#) and [AF023155.1](#).

Summary: Epidermal growth factor has a profound effect on the differentiation of specific cells in vivo and is a potent mitogenic factor for a variety of cultured cells of both ectodermal and mesodermal origin. The EGF precursor is believed to exist as a membrane-bound molecule which is proteolytically cleaved to generate the 53-amino acid peptide hormone that stimulates cells to divide.

Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.

FEATURES	Location/Qualifiers
source	1..1207 /organism="Homo sapiens" /db_xref="taxon:9606" /chromosome="4" /map="4q25"
Protein	1..1207 /product="epidermal growth factor (beta-urogastrone)" /note="urogastrone"
<u>sig peptide</u>	1..22 /calculated_mol_wt=2392
<u>Region</u>	151..189 /region_name="LY" /note="Low-density lipoprotein-receptor YWTD domain; Type 'B' repeats in low-density lipoprotein (LDL) receptor that plays a central role in mammalian cholesterol metabolism. Also present in a variety of molecules similar to gp300/megalin; smart00135" /db_xref="CDD:47474"
<u>Region</u>	<352..393 /region_name="vWA Matrilin" /note="vWA Matrilin: In cartilaginous plate, extracellular matrix molecules mediate cell-matrix and matrix-matrix interactions thereby providing tissue integrity. Some members of the matrilin family are expressed specifically in developing cartilage rudiments; cd01475" /db_xref="CDD:29248"
<u>Region</u>	505..546 /region_name="LY" /note="Low-density lipoprotein-receptor YWTD domain; Type 'B' repeats in low-density lipoprotein (LDL) receptor that plays a central role in mammalian cholesterol metabolism. Also present in a variety of molecules similar to gp300/megalin; smart00135" /db_xref="CDD:47474"
<u>Region</u>	547..587 /region_name="LY" /note="Low-density lipoprotein-receptor YWTD domain; Type 'B' repeats in low-density lipoprotein (LDL) receptor that plays a central role in mammalian cholesterol metabolism. Also present in a variety of molecules similar to gp300/megalin; smart00135" /db_xref="CDD:47474"
<u>Region</u>	590..633

```

/region_name="LY"
/note="Low-density lipoprotein-receptor YWTD domain; Type
'B' repeats in low-density lipoprotein (LDL) receptor that
plays a central role in mammalian cholesterol metabolism.
Also present in a variety of molecules similar to
gp300/megalin; smart00135"
/db_xref="CDD:47474"
Region 635..676
/region_name="LY"
/note="Low-density lipoprotein-receptor YWTD domain; Type
'B' repeats in low-density lipoprotein (LDL) receptor that
plays a central role in mammalian cholesterol metabolism.
Also present in a variety of molecules similar to
gp300/megalin; smart00135"
/db_xref="CDD:47474"
Region 677..718
/region_name="LY"
/note="Low-density lipoprotein-receptor YWTD domain; Type
'B' repeats in low-density lipoprotein (LDL) receptor that
plays a central role in mammalian cholesterol metabolism.
Also present in a variety of molecules similar to
gp300/megalin; smart00135"
/db_xref="CDD:47474"
Region <740..779
/region_name="vWA_Matrilin"
/note="vWA_Matrilin: In cartilaginous plate, extracellular
matrix molecules mediate cell-matrix and matrix-matrix
interactions thereby providing tissue integrity. Some
members of the matrilin family are expressed specifically
in developing cartilage rudiments; cd01475"
/db_xref="CDD:29248"
Region 870..910
/region_name="EGF_CA"
/note="Calcium-binding EGF-like domain; smart00179"
/db_xref="CDD:47510"
Region 912..>940
/region_name="EGF_CA"
/note="Calcium binding EGF domain; pfam07645"
/db_xref="CDD:71088"
mat_peptide 971..1023
/product="epidermal growth factor"
/calculated_mol_wt=6222
Site 1022
/site_type="modified"
/experiment="experimental evidence, no additional details
recorded"
/note="proteolytic cleavage site"
/citation=[6]
/citation=[7]
/db_xref="HPRD:00273"
CDS 1..1207
/gene="EGF"
/coded_by="NM_001963.2:443..4066"
/GO_component="extracellular region [PMID 9712850];
integral to membrane; nucleus; plasma membrane [PMID
3491360]"
/GO_function="calcium ion binding; epidermal growth factor
receptor activating ligand activity [PMID 9712850]; growth
factor activity [PMID 7736574]; protein binding [PMID
2790960]"

```

```

/GO_process="activation of MAPK activity [PMID 9482941];
chromosome organization and biogenesis (sensu Eukaryota)
[PMID 10436156]; DNA replication [PMID 9482941]; epidermal
growth factor receptor signaling pathway; positive
regulation of cell proliferation [PMID 7736574]"
/db_xref="CCDS:CCDS3689.1"
/db_xref="GeneID:1950"
/db_xref="HGNC:3229"
/db_xref="HPRD:00578"
/db_xref="MIM:131530"

```

ORIGIN

```




1 mlltliillp vvsksfsvsl sapqhwscpe gtlagnngnst cvgpapflif shgnsifrid
61 tegtnyeqlv vdagvsvimd fhynekriyw vlderqllqr vflngsrqer vonieknvsg
121 mainwineev iwsnqgegii tvtdmkgnns hillsalkyp anvavdpver fifwssevag
181 slyradldgv gvkalletse kitavslavl dkrflwiqyn regsnslcs cdydggsvhi
241 skhptqhnlf amslfgdrif ystwkmkti iankhtgkdm vrinlhssfv plgelkvvhp
301 laqpkaeddt wepeqklckl rkgnscstvc gqdlqshlcm caegyalsrd rkycedvnc
361 afwnhgctlg cknatpssyc tcpvgfvllp dgkrchqlvs cprnvsecsh dcvltssegpl
421 cfcpegsvle rdgkctscgs spdnggcsql cvplspvswe cdcfpgydlq ldekscaasg
481 pqpflifans qdirhmfhdg tdygtllsqq gmmvvaldhd pvenkiyfah talkwieran
541 mdgsgqrerli eegvdvpegl avdwigrffy wtdrgkslig rsdlngrksk iitkenisgp
601 rgiavhpmak rlfwttdgin priessslgg lgrlviassd liwpsgitid fltdklywcd
661 akgsvieman ldgskrrrlt qndvgbpfav avfedyvfwf dwampsvirv nkrtgkdrvr
721 lqgsmkpsl lvvvhplakp gadpclyqng gcehickkrl gtawcscreg fmkasdgkct
781 laldghqla ggevdlnkv tpldilsctr vsednitesq hmlvaeimvs dqddcapvcg
841 smyarciseg edatcqclkg fagdgklcsd idecemgvvp cpassckcin teggyvcrs
901 egyqgdgihc ldidecqlgv hscgenasct ntegygtcmc agrlsepgli cpdstppphl
961 reddhysvr nsdsecplsh dgyclhdgvc myiealdkya cncvvgyige rcqyrdlkww
1021 elrhaghggq qkvivvavc vvlvmllls lwgahyyrtz kllsknpknp yeessrdvrs
1081 rrpatedgdm ssqpgwfvw ikehqdlkng ggpvagedgq aadgsmqpts wrqepqlcgm
1141 gteggcwipv ssqgscpqr mersfhmpsy gtqtleggve kphsllsanp lwqqrldpp
1201 hqmelqtq

```

//

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

Aug 28 2007 16:53:42

[PubMed](#)
[Nucleotide](#)
[Protein](#)
[Genome](#)
[Structure](#)
[PMC](#)
[Taxonomy](#)
[OMIM](#)
[Books](#)

[Search](#)
[Protein](#)
[for](#)
[Limits](#)
[Preview/Index](#)
[History](#)
[Clipboard](#)
[Details](#)

[Go](#)
[Clear](#)

[Display](#)
[GenPept](#)
[Show](#)

[Send to](#)

Range: from to end
 Features: ☒ CDD [Refresh](#)

☐ 1: [AAA64297](#). Reports hepatocyte growth...[gi:337938]

[BLink](#), [Conserved Domains](#), [Links](#)

[Features](#) [Sequence](#)

LOCUS AAA64297 723 aa linear PRI 24-MAR-1995
 DEFINITION hepatocyte growth factor.
 ACCESSION AAA64297
 VERSION AAA64297.1 GI:337938
 DBSOURCE locus HUMSCFA2 accession [M73240.1](#)
 KEYWORDS .
 SOURCE Homo sapiens (human)
 ORGANISM [Homo sapiens](#)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
 Catarrhini; Hominidae; Homo.
 REFERENCE 1 (residues 1 to 723)
 AUTHORS Weidner,K.M., Arakaki,N., Hartmann,G., Vandekerckhove,J.S.,
 Weingart,S., Rieder,H., Fonatsch,C., Tsubouchi,H., Hishida,T.,
 Daikuhara,Y. and Birchmeier,W.
 TITLE Evidence for the identity of human scatter factor and human
 hepatocyte growth factor
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 88 (16), 7001-7005 (1991)
 PUBMED [1831266](#)
 COMMENT Method: conceptual translation.
 FEATURES
 source
 Location/Qualifiers
 1..723
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /map="7q21"
 /clone="SF2"
 /cell_line="MRC-5"
 /cell_type="fibroblast"
 /dev_stage="embryo"
[Protein](#) 1..723
 /product="hepatocyte growth factor"
[sig_peptide](#) 1..31
 /gene="HGF"
 /note="G00-127-524"
[Region](#) 39..122
 /region_name="PAN APPLE"
 /note="PAN/APPLE-like domain; present in N-terminal (N)
 domains of plasminogen/ hepatocyte growth factor proteins,
 plasma prekallikrein/coagulation factor XI and microneurone
 antigen proteins, plant receptor-like protein kinases, and
 various nematode and leech ant; cd00129"
 /db_xref="CDD:29031"

```

Site      order(60,62,73)
          /site_type="other"
          /note="putative binding site"
          /db_xref="CDD:29031"
Region    126..202
          /region_name="KR"
          /note="Kringle domain; Kringle domains are believed to
          play a role in binding mediators, such as peptides, other
          proteins, membranes, or phospholipids; cd00108"
          /db_xref="CDD:29008"
Site      137
          /site_type="other"
          /note="putative domain interaction site"
          /db_xref="CDD:29008"
Site      order(152,162,183,185,193)
          /site_type="other"
          /note="ligand binding site"
          /db_xref="CDD:29008"
Region    203..284
          /region_name="KR"
          /note="Kringle domain; Kringle domains are believed to
          play a role in binding mediators, such as peptides, other
          proteins, membranes, or phospholipids; cd00108"
          /db_xref="CDD:29008"
Site      215
          /site_type="other"
          /note="putative domain interaction site"
          /db_xref="CDD:29008"
Site      order(230,240,265,267,275)
          /site_type="other"
          /note="ligand binding site"
          /db_xref="CDD:29008"
Region    297..379
          /region_name="KR"
          /note="Kringle domain; Kringle domains are believed to
          play a role in binding mediators, such as peptides, other
          proteins, membranes, or phospholipids; cd00108"
          /db_xref="CDD:29008"
Site      309
          /site_type="other"
          /note="putative domain interaction site"
          /db_xref="CDD:29008"
Site      order(324,334,359,361,369)
          /site_type="other"
          /note="ligand binding site"
          /db_xref="CDD:29008"
Region    383..465
          /region_name="KR"
          /note="Kringle domain; Kringle domains are believed to
          play a role in binding mediators, such as peptides, other
          proteins, membranes, or phospholipids; cd00108"
          /db_xref="CDD:29008"
Site      395
          /site_type="other"
          /note="putative domain interaction site"
          /db_xref="CDD:29008"
Site      order(410,420,446,448,456)
          /site_type="other"
          /note="ligand binding site"
          /db_xref="CDD:29008"

```

```

Region      490..714
            /region_name="Tryp_SPc"
            /note="Trypsin-like serine protease; Many of these are
            synthesized as inactive precursor zymogens that are
            cleaved during limited proteolysis to generate their
            active forms; cd00190"
            /db_xref="CDD:29152"

Site        490
            /site_type="cleavage"
            /db_xref="CDD:29152"

Site        order(529,573,668)
            /site_type="active"
            /db_xref="CDD:29152"

Site        order(662,687,689)
            /site_type="other"
            /note="substrate binding sites"
            /db_xref="CDD:29152"

CDS         1..723
            /gene="HGF"
            /standard_name="hepapoietin A; scatter factor"
            /coded_by="M73240.1:66..2237"
            /db_xref="GDB:G00-127-524"

```

ORIGIN

```




1  mwvtkllpal llqhvllhll llpiaipya gqrkrrntih efkksakttl ikidpalkik
61  tkkvntadqc anrctrnkgl pftckafvfd karkqclwfp fnsmsgvkk efghefdlye
121 nkdyirncii gkgrsykgvt sitksgikcq pwssmipheh syrgkdlqen ycrnprgeeg
181 gpwcfstnpe vryevcdipq csevecmtcn gesyrglmdh tesgkicqrw dhqtrphrhkf
241 lperypdkgf ddnycrnpdg qprpwcyltd phtrweycai ktcadntmnd tdvplettec
301 igggqgegyrg tvntiwnqip cqrwdsqyph ehdmtpenf kckdlrenyrc npdgsespsc
361 ftt dpnirvg ycsqipncdm shgqdcyrgn gknygmnlsg trsgltscmw dknmedlhrh
421 ifwepdaskl nenycrnpdd dahgpwcytg nplipwdycp isrcegdttp tivnldhpvi
481 skactkqlrv vngipttrtni gwmvslryrn khicggslik eswvltarqc fpsrdlkdye
541 awlgihdvhg rgdekckqvl nvsqlvygpe gsdvlvmkla rpavlddfvs tidlpnygct
601 ipektscsvy gwgytglnly dgllrvahly imgnekcsqh hrgkvtlnes eicagaekig
661 sgpcegdyyg plvceghkmr mvlgvivpgr gcaipnrpgi fvravayyakw inhkiiltykv
721 pqs

```

//

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

Aug 28 2007 16:53:42

[PubMed](#)
[Nucleotide](#)
[Protein](#)
[Genome](#)
[Structure](#)
[PMC](#)
[Taxonomy](#)
[OMIM](#)
[Books](#)

[My NCBI](#)
[\[Sign In\]](#)
[\[Regis\]](#)

Search **Protein** for

[Limits](#)
[Preview/Index](#)
[History](#)
[Clipboard](#)
[Details](#)

Display **GenPept** Show **5** Send to

Range: from begin to end Features: ☒ CDD

☐ 1: NP_001997. Reports fibroblast growth...[gi:153285461]

[BLink](#), [Conserved Domains](#), [Links](#)

[Comment](#) [Features](#) [Sequence](#)

LOCUS NP_001997 288 aa linear PRI 22-OCT-2007
 DEFINITION fibroblast growth factor 2 [Homo sapiens].

ACCESSION NP_001997

VERSION NP_001997.5 GI:153285461

DBSOURCE REFSEQ: accession [NM_002006.4](#)

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM [Homo sapiens](#)

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.

REFERENCE 1 (residues 1 to 288)

AUTHORS Shi,Y.H., Bingle,L., Gong,L.H., Wang,Y.X., Corke,K.P. and Fang,W.G.

TITLE Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells

JOURNAL Pathology 39 (4), 396-400 (2007)

PUBMED [17676480](#)

REMARK GeneRIF: bFGF augments hypoxia induced VEGF release in breast cancer cells mainly through the PI3K pathway and partly depending on HIF-1 activity.

REFERENCE 2 (residues 1 to 288)

AUTHORS D'Sa,C., Gross,J., Francione,V.P. and Morest,D.K.

TITLE Plasticity of synaptic endings in the cochlear nucleus following noise-induced hearing loss is facilitated in the adult FGF2 overexpressor mouse

JOURNAL Eur. J. Neurosci. 26 (3), 666-680 (2007)

PUBMED [17651425](#)

REMARK GeneRIF: FGF2 may contribute to the synaptic reorganization after noise damage; it may protect and/or aid recovery of synapses after overstimulation.

REFERENCE 3 (residues 1 to 288)

AUTHORS Kakudo,N., Shimotsuma,A. and Kusumoto,K.

TITLE Fibroblast growth factor-2 stimulates adipogenic differentiation of human adipose-derived stem cells

JOURNAL Biochem. Biophys. Res. Commun. 359 (2), 239-244 (2007)

PUBMED [17543283](#)

REMARK GeneRIF: Fibroblast growth factor-2 stimulates adipogenic differentiation of human adipose-derived stem cells

REFERENCE 4 (residues 1 to 288)

AUTHORS Ribatti,D., Vacca,A., Rusnati,M. and Presta,M.

TITLE The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies

JOURNAL Cytokine Growth Factor Rev. 18 (3-4), 327-334 (2007)
 PUBMED [17537668](#)
 REMARK GeneRIF: FGF2 has a role in tumor angiogenesis associated with haematological malignancies [review]
 Review article
 REFERENCE 5 (residues 1 to 288)
 AUTHORS Arnaud,E., Touriol,C., Boutonnet,C., Gensac,M.C., Vagner,S., Prats,H. and Prats,A.C.
 TITLE A new 34-kilodalton isoform of human fibroblast growth factor 2 is cap dependently synthesized by using a non-AUG start codon and behaves as a survival factor
 JOURNAL Mol. Cell. Biol. 19 (1), 505-514 (1999)
 PUBMED [9858574](#)
 REMARK GeneRIF: A new FGF2 isoform results from the use of a non-AUG (CUG) translation initiation codon.
 REFERENCE 6 (residues 1 to 288)
 AUTHORS Watson,R., Anthony,F., Pickett,M., Lambden,P., Masson,G.M. and Thomas,E.J.
 TITLE Reverse transcription with nested polymerase chain reaction shows expression of basic fibroblast growth factor transcripts in human granulosa and cumulus cells from in vitro fertilisation patients
 JOURNAL Biochem. Biophys. Res. Commun. 187 (3), 1227-1231 (1992)
 PUBMED [1417798](#)
 REFERENCE 7 (residues 1 to 288)
 AUTHORS Ago,H., Kitagawa,Y., Fujishima,A., Matsuura,Y. and Katsube,Y.
 TITLE Crystal structure of basic fibroblast growth factor at 1.6 Å resolution
 JOURNAL J. Biochem. 110 (3), 360-363 (1991)
 PUBMED [1769963](#)
 REFERENCE 8 (residues 1 to 288)
 AUTHORS Eriksson,A.E., Cousens,L.S., Weaver,L.H. and Matthews,B.W.
 TITLE Three-dimensional structure of human basic fibroblast growth factor
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 88 (8), 3441-3445 (1991)
 PUBMED [1707542](#)
 REFERENCE 9 (residues 1 to 288)
 AUTHORS Zhu,X., Komiya,H., Chirino,A., Faham,S., Fox,G.M., Arakawa,T., Hsu,B.T. and Rees,D.C.
 TITLE Three-dimensional structures of acidic and basic fibroblast growth factors
 JOURNAL Science 251 (4989), 90-93 (1991)
 PUBMED [1702556](#)
 REFERENCE 10 (residues 1 to 288)
 AUTHORS Prats,H., Kaghad,M., Prats,A.C., Klagsbrun,M., Lelias,J.M., Liauzun,P., Chalon,P., Tauber,J.P., Amalric,F., Smith,J.A. et al.
 TITLE High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 86 (6), 1836-1840 (1989)
 PUBMED [2538817](#)
 REMARK GeneRIF: Alternate protein isoforms arise through the use of AUG and non-AUG (CUG) translation initiation codons.
 COMMENT REVIEWED REFSEQ: This record has been curated by NCBI staff. The reference sequence was derived from [J04513.1](#), [AC021205.6](#), [M27968.1](#), [BU501243.1](#), [BP292299.1](#), [CN315083.1](#) and [AA256481.1](#).
 On Jul 24, 2007 this sequence version replaced [gi:41352695](#).

Summary: The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members bind heparin and possess broad mitogenic and angiogenic activities. This protein has been implicated in diverse biological processes, such as limb and nervous system development, wound healing, and tumor

growth. The mRNA for this gene contains multiple polyadenylation sites, and is alternatively translated from non-AUG (CUG) and AUG initiation codons, resulting in five different isoforms with distinct properties. The CUG-initiated isoforms are localized in the nucleus and are responsible for the intracrine effect, whereas, the AUG-initiated form is mostly cytosolic and is responsible for the paracrine and autocrine effects of this FGF.

Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.

FEATURES	Location/Qualifiers
<u>source</u>	1..288 /organism="Homo sapiens" /db_xref="taxon:9606" /chromosome="4" /map="4q26-q27"
<u>Protein</u>	1..288 /product="fibroblast growth factor 2" /note="heparin-binding growth factor 2; prostatin; basic fibroblast growth factor bFGF" /calculated_mol_wt=30639
<u>Region</u>	79 /region_name="24-kDa isoform; alternative non-AUG (CUG) translation initiation site"
<u>Region</u>	88 /region_name="22.5-kDa isoform; alternative non-AUG (CUG) translation initiation site"
<u>Region</u>	93 /region_name="22-kDa isoform; alternative non-AUG (CUG) translation initiation site"
<u>Region</u>	134 /region_name="18-kDa isoform; alternative AUG translation initiation site"
<u>Region</u>	163..285 /region_name="FGF" /note="Acidic and basic fibroblast growth factor family; FGFs are mitogens, which stimulate growth or differentiation of cells of mesodermal or neuroectodermal origin; cd00058" /db_xref="CDD:28940"
<u>Site</u>	order(163,166,198,200,202,230,238,241..246,248,280,282, 284) /site_type="other" /note="receptor interaction site" /db_xref="CDD:28940"
<u>Site</u>	order(261..262,267,271,277) /site_type="other" /note="heparin binding site (glycine box)" /db_xref="CDD:28940"
<u>CDS</u>	1..288 /gene="FGF2" /coded_by="NM_002006.4:69..935" /exception="alternative start codon" /GO_component="extracellular region [PMID 10490103]; extracellular space [PMID 2435575]" /GO_function="growth factor activity; heparin binding; protein binding [PMID 11075807]" /GO_process="activation of MAPK activity [PMID 9712850]; angiogenesis; cell differentiation; cell proliferation;

cell-cell signaling; chemotaxis [PMID 10848592]; muscle development; nervous system development [PMID 9576942]; organ morphogenesis [PMID 10903182]; positive regulation of cell proliferation [PMID 2435575]; Ras protein signal transduction [PMID 10848592]; regulation of progression through cell cycle; signal transduction [PMID 9712850]"
/note="non-AUG (CUG) translation initiation codon; 34-kDa isoform"
/db_xref="CCDS:CCDS34059.1"
/db_xref="GeneID:2247"
/db_xref="HGNC:3676"
/db_xref="HPRD:00622"
/db_xref="MIM:134920"

ORIGIN

```
1  mvgvgggdve  dvtprpggcq  isgrgargcn  gipgaaawea  alprrrprrh  psvnprraa
61  gsprrtrgrrt  eerpsgrlrg  drgrgralpg  grlggrgrgr  apervggrgr  grgtaapraa
121  paargsrpgp  agtmaagsit  tlpalpedgg  sgafppghfk  dpkrlyckng  gfflrhpdg
181  rvdgvreksd  phiklqlgae  ergvvsikgv  canrylamke  dgrllaskcv  tdecfferl
241  esnnyntyrs  rkytswyval  krtgqykigs  ktgpgqkail  flpmsaks
```

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Aug 28 2007 16:53:42



Blast 2 Sequences results

[PubMed](#)[Entrez](#)[BLAST](#)[OMIM](#)[Taxonomy](#)[Structure](#)

BLAST 2 SEQUENCES RESULTS VERSION BLASTP 2.2.17 [Aug-26-2007]

Matrix BLOSUM62 gap open: 11 gap extension: 1

x_dropoff: 0 expect: 10.0000 wordsize: 3 [Filter](#) ☐ View option Standard

Masking character option X for protein, n for nucleotide Masking color option Black

☐ Show CDS translation [Align](#)

Sequence 1: unnamed protein product *EGF*
Length = 1207

Sequence 2: unnamed protein product *HGF*
Length = 723

No significant similarity was found

CPU time: 0.03 user secs. 0.02 sys. secs. 0.05 total secs.



Blast 2 Sequences results

[PubMed](#)[Entrez](#)[BLAST](#)[OMIM](#)[Taxonomy](#)[Structure](#)

BLAST 2 SEQUENCES RESULTS VERSION BLASTP 2.2.17 [Aug-26-2007]

Matrix BLOSUM62 gap open: 11 gap extension: 1

x_dropoff: 0 expect: 10.000 wordsize: 3 [Filter](#) ☐ View option Standard

Masking character option X for protein, n for nucleotide Masking color option Black

☐ Show CDS translation [Align](#)

Sequence 1: unnamed protein product **EGF**
Length = 1207

Sequence 2: unnamed protein product **FGF-2**
Length = 288

No significant similarity was found

CPU time: 0.04 user secs. 0.01 sys. secs. 0.05 total secs.



Blast 2 Sequences results

[PubMed](#)[Entrez](#)[BLAST](#)[OMIM](#)[Taxonomy](#)[Structure](#)

BLAST 2 SEQUENCES RESULTS VERSION BLASTP 2.2.17 [Aug-26-2007]

Matrix BLOSUM62 gap open: 11 gap extension: 1

x_dropoff: 0 expect: 10.0000 wordsize: 3 Filter ☐ View option Standard

Masking character option X for protein, n for nucleotide Masking color option Black

☐ Show CDS translation

Sequence 1: unnamed protein product *HGF*
Length = 723

Sequence 2: unnamed protein product *FGF-2*
Length = 288

No significant similarity was found

CPU time: 0.03 user secs. 0.02 sys. secs 0.05 total secs.